PepGen reports robust splicing correction in DM1 trial; 29.1% mean correction at 10 mg/kg single dose

PepGen Inc.

Mean splicing correction of 12.3% (5 mg/kg, n=6) and 29.1% (10 mg/kg, n=4) at 28 days post single dose.
Favorable emerging safety profile; one treatment-related SAE of abdominal pain potentially confounded.
Cash $120.2M as of Dec 31, 2024, expected to fund operations into 2026.
Net loss $90.0M for FY2024 ($2.85/share) vs $78.6M ($3.30/share) in FY2023.
15 mg/kg cohort results expected H2 2025; CONNECT1-EDO51 10 mg/kg fully enrolled with results Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.